Denver City & County, Colo.'s Wastewater Revenue Bonds Rated 'AA'; Outlook Stable Mar 02

  • ID: 2035325
  • March 2002
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) March 13, 2002Standard & Poor's today assigned its double-'A' rating to Denver City and County, Colo.'s $30.875 million wastewater revenue bonds series 2002 dated April 1, 2002, due Nov. 1, 2022. The bonds are scheduled to sell on March 19, 2002. The outlook is stable. The bonds are secured by a pledge of net revenues from the city's wastewater fund, after operations and maintenance expenses. Pledged wastewater fund revenues include both sanitary sewer fees and storm water drainage taxes, but exclude connection and developer fees. The rating reflects: -- A very large and diverse customer and tax base covering the city and county of Denver, which continues to serve as a regional economic hub for...

Companies mentioned in this report are:
- Denver City & Cnty

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Denver City & Cnty

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown





Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.